These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17337474)

  • 1. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function.
    Hueber AJ; Tunc A; Schett G; Manger B
    Ann Rheum Dis; 2007 Jul; 66(7):981-2. PubMed ID: 17337474
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.
    Brulhart L; Ciurea A; Finckh A; Notter A; Waldburger JM; Kyburz D; Gabay C
    Ann Rheum Dis; 2006 Sep; 65(9):1255-7. PubMed ID: 16540545
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-tumour necrosis factor {alpha} therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment.
    Naumann L; Huscher D; Detert J; Spengler M; Burmester GR; Buttgereit F
    Ann Rheum Dis; 2009 Dec; 68(12):1934-6. PubMed ID: 19910303
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
    Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
    [No Abstract]   [Full Text] [Related]  

  • 7. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.
    Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D
    Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumour necrosis factor therapy in the West Midlands.
    Bartram D; Sheeran T; Price T; Mulherin D
    Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
    [No Abstract]   [Full Text] [Related]  

  • 9. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor alpha agents.
    Martínez-Martínez MU; Cuevas-Orta E; Reyes-Vaca G; Baranda L; González-Amaro R; Abud-Mendoza C
    Ann Rheum Dis; 2007 Jan; 66(1):134-5. PubMed ID: 17178761
    [No Abstract]   [Full Text] [Related]  

  • 10. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 13. Swollen joint count as a predictor of response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis: comment on the article by Sokka and Pincus.
    Estrach C; Mpofu S; Thompson RN; Williams E; Abernethy VE; Moots RJ
    Arthritis Rheum; 2003 Dec; 48(12):3611-3; author reply 3613-5. PubMed ID: 14674016
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.
    Ng CT; Radovits BJ; Kievit W; Fransen J; van Riel PL; FitzGerald O; Veale DJ; Bresnihan B
    Ann Rheum Dis; 2010 Jan; 69(1):313-4. PubMed ID: 20007623
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP; Taggart AJ
    Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis.
    Alcorn N; Tierney A; Wu O; Gilmour H; Madhok R
    Ann Rheum Dis; 2010 Aug; 69(8):1571. PubMed ID: 20388741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.